Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 893113 | ISIN: FR0000131906 | Ticker-Symbol: RNL
Tradegate
21.01.25
20:16 Uhr
48,260 Euro
-0,020
-0,04 %
1-Jahres-Chart
RENAULT SA Chart 1 Jahr
5-Tage-Chart
RENAULT SA 5-Tage-Chart
RealtimeGeldBriefZeit
48,25048,34007:40
48,45048,64007:41
GlobeNewswire (Europe)
63 Leser
Artikel bewerten:
(0)

Duncan Minto appointed Chief Financial Officer of Renault Group

Finanznachrichten News
PRESS RELEASE
January 21, 2025

DUNCAN MINTO APPOINTED CHIEF FINANCIAL OFFICER OF RENAULT GROUP

Boulogne-Billancourt, 21st January 2025 - Renault Group is pleased to announce that Duncan Minto will become the company's new Chief Financial Officer, effective March 1st, replacing Thierry Piéton.

Thierry Piéton has decided to take up a new professional challenge, to be announced shortly.
His departure from the company will take effect on 28 February 2025.

Duncan Minto is currently Chief Financial Officer of Alpine, a position he has held since October 2023. He will be a member of the Leadership Team, reporting to Luca de Meo, CEO of Renault Group.

Luca de Meo, CEO of Renault Group, said: "Thanks to his 25 years' experience in finance and his extensive knowledge of the Group, and the automotive industry, Duncan will be fully primed to continue and even accelerate the actions already underway. He will play a strategic role in the transformation of the Group and in the successful execution of the plan to unleash the full potential of our company."

Luca de Meo also paid tribute to the work of Thierry Piéton: "Thierry has played an essential role in implementing Renault Group's strategy, both in terms of performance management and his strong involvement in our structuring projects, and in improving the way the Group is perceived by the financial markets. On behalf of all our teams, I would like to thank him warmly for his commitment and wish him every success in his new projects."

Thierry Piéton said: "The 9 years I have spent with Renault Group have been the most stimulating and intense of my career. I am proud to have contributed to the deployment of the Group's strategy and to its operational turnaround. I would like to thank our teams, with whom it has been such a pleasure to work, for their commitment, and our investors and financial partners for their confidence. I am leaving a Group that is now solid and successful, ready to meet the challenges of its industry."


RENAULT GROUP MEDIA RELATIONS


Valérie GILLOT
+33 6 83 92 92 96
valerie.gillot@renault.com


Rie Yamane
+33 6 03 16 35 20
rie.yamane@renault.com



RENAULT GROUP INVESTOR RELATIONS
Philippine de Schonen
+33 6 13 45 68 39
Philippine.de-schonen@renaut.com


About Renault Group
Renault Group is at the forefront of a mobility that is reinventing itself. The Group relies on the complementarity of its 4 brands - Renault - Dacia - Alpine and Mobilize - and offers sustainable and innovative mobility solutions to its customers. Established in more than 130 countries, Renault Group sold 2.264 million vehicles in 2024. It employs more than 105,000 people who embody its Purpose every day, so that mobility brings people closer.
Ready to pursue challenges both on the road and in competition, the Group is committed to an ambitious and value-generating transformation focused on the development of new technologies and services, and a new range of even more competitive, balanced, and electrified vehicles. In line with environmental challenges, the Group's ambition is to achieve carbon neutrality in Europe by 2040.
More information: https://www.renaultgroup.com/en/


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.